Deuterated CFTR potentiators

Patent metadata

Field	Value
Publication number	US-9512079-B2
Application number	US-201514921158-A
Country	US
Kind code	B2
Filing date	Oct 23, 2015
Priority date	May 18, 2011
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

This invention relates to compounds of Formula I:

and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.

First claim

What is claimed is:

1. A compound represented by the formula:

or a pharmaceutically acceptable salt thereof, wherein any atom not designated as deuterium is present at its natural isotopic abundance, and wherein the deuterium incorporation at each designated deuterium atom is at least 90%.

2. The compound of claim 1 , wherein the compound is Compound 106, or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

4. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 3 .

5. A method of treating COPD in a subject in need thereof, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 3 .

6. The compound of claim 1 , wherein the compound is Compound 105, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the deuterium incorporation at each designated deuterium atom is at least 95%.

8. The compound of claim 1 , wherein the deuterium incorporation at each designated deuterium atom is at least 97%.

9. The compound of claim 2 , wherein the deuterium incorporation at each designated deuterium atom is at least 95%.

10. The compound of claim 2 , wherein the deuterium incorporation at each designated deuterium atom is at least 97%.

11. The compound of claim 6 , wherein the deuterium incorporation at each designated deuterium atom is at least 95%.

12. The compound of claim 6 , wherein the deuterium incorporation at each designated deuterium atom is at least 97%.

13. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 2 .

14. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 9 .

15. A method of treating cystic fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 10 .

Assignees

• Concert Pharmaceuticals Inc

Inventors

• Morgan Adam J

Classifications

• C07D215/56 Primary

  with oxygen atoms in position 4 · CPC title

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• C07B59/002

  Heterocyclic compounds · CPC title